

INOVIQ INVESTOR BRIEFING

INOVIQ Limited (ASX:I IQ) (**INOVIQ** or the **Company**) advises that it will host an online Investor Briefing on our EXO-OC test and CAR-exosome therapy on **Monday, 14th July 2025 at 3:00pm – 3:30pm AEST**.

The agenda for the investor briefing includes:

- Overview of the EXO-OC ovarian cancer test and recent results for the early detection of ovarian cancer
- Update on CAR-exosome therapy and recent in vitro data in breast and lung cancers
- Summary and Q&A

MST Senior Life Sciences Analyst, Chris Kallos, who recently prepared the updated Research Report on INOVIQ, will host the Q&A session.

The details and link to register for the webinar are provided below:

Date: Monday, 14 July 2025

Time: 3:00 PM AEST

Registration: https://us06web.zoom.us/webinar/register/WN_NyAlZpVRR2yfPC3gu_oGDQ

Once the registration form is completed, investors will receive a confirmation email detailing how to access the briefing online. A link to the recorded briefing will be included on the INOVIQ website at [click here](#).

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: I IQ) is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. Our product portfolio spans commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical-stage CAR-exosome therapeutic program targeting solid tumours. Through scientific excellence and innovation, INOVIQ is shaping the future of cancer detection and treatment. For more information on INOVIQ, visit www.inoviq.com.